Novaptech

Executive Summary

Novaptech is a French biotechnology company specializing in aptamer-based technologies, operating as a contract research organization (CRO) since its founding in 2016. The company leverages proprietary SELEX and biosensor platforms to provide custom aptamer selection, characterization, and optimization services for diagnostic, therapeutic, and analytical applications. By serving diverse sectors including pharmaceuticals, life sciences, agri-food, and environmental testing, Novaptech addresses growing demand for rapid, multiplexed molecular detection tools. Its technology offers advantages in specificity, stability, and cost-effectiveness compared to traditional antibodies, positioning the company as a key player in the expanding aptamer market. As a CRO, Novaptech benefits from recurring revenue streams and partnerships with research institutions and industry players seeking tailored aptamer solutions. The company's focus on both therapeutic and diagnostic applications provides diversified growth opportunities, though it faces competition from established antibody-based platforms and other aptamer developers. With its strong intellectual property and expertise in SELEX technology, Novaptech is well-positioned to capitalize on the increasing adoption of aptamers in precision medicine, food safety, and environmental monitoring.

Upcoming Catalysts (preview)

• Q4 2026Major pharmaceutical collaboration for therapeutic aptamer development40% success
• Q1 2027Launch of new multiplexed diagnostic test platform65% success
• Q2 2026Securing grant or funding for expansion into agri-food sector70% success